What Tempus AI's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Tempus AI filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition announced, acquisition completed and AI investment.
Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn
Get Tempus AI's live signals in Claude or ChatGPT, or by API
What changed at Tempus AI this week? Use Autobound signals for tempus.com.- Filed
- Nov 2, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 13
Source: Autobound Signal API · 97 signals tracked for Tempus AI · updated
10-Q · latest 10
What Tempus AI's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
Tempus Collaborates with AstraZeneca and Pathos to Build Foundation Multimodal Oncology AI Model
Tempus entered agreements with AstraZeneca and Pathos to develop and validate a foundation large multimodal model in oncology using de-identified datasets.
$10M
paid to Pathos in October 2026 under the Pathos Master Agreement for Foundation Model commitments
foundation large multimodal modelAIPathos
Tempus AI announced definitive agreement to acquire Personalis for $1.5 billion enterprise value
On July 20, 2026, Tempus AI entered into an Agreement and Plan of Merger to acquire all outstanding shares of Personalis for $16.25 per share, representing an enterprise value of $1.5 billion, with closing anticipated in Q4 2026.
$1.5B
total enterprise value to acquire Personalis
Tom Schoenherr appointed Chairman of Ambry Genetics, stepping down as CEO, Diagnostics
Effective November 1, 2026, Tom Schoenherr was appointed Chairman of wholly-owned subsidiary Ambry Genetics Corp.
Tempus raised $460.0 million via 0.00% Convertible Senior Notes due 2032 to repay debt
On May 12, 2026, Tempus completed an offering of $460.0 million of 0.00% Convertible Senior Notes due 2032, generating net proceeds of $442.0 million.
$460M
aggregate principal amount of 0.00% Convertible Senior Notes due 2032
Tempus AI completed acquisition of Center Health for $5.4 million cash plus stock
On August 7, 2026, Tempus AI completed the acquisition of Center Health Incorporated, merging it into Center Health Sub, LLC for $5.4 million in cash and 255,885 shares of Class A common stock.
$5.4M
cash consideration for Center Health acquisition
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
Tempus AI Announces $1.5 Billion Acquisition of Personalis Expected to Close Late 2026/Early 2027
Tempus entered into a Merger Agreement to acquire Personalis for $16.25 per share representing an enterprise value of $1.5 billion.
$1.5B
total enterprise value for the acquisition of Personalis
Tempus AI Expands Healthcare Data Platform with $89.9M Technology Investment in 1H 2026
Tempus continues heavy development of its proprietary operating system and data pipes connecting physicians, diagnostic labs, and life science companies.
$89.9M
invested in technology in the six months ended June 30, 2026
AIgenerative AI
Tempus Collaborates with AstraZeneca and Pathos to Build Multi-Modal Oncology AI Foundation Model
Under agreements with AstraZeneca and Pathos, Tempus is participating in the development, validation, and maintenance of an oncology foundation large multimodal model using de-identified datasets, with Tempus receiving a license to the completed model.
foundation large multimodal modelAIgenerative AIPathos
On May 12, 2026, Tempus AI completed a private offering of $460.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, generating net proceeds of $441.9 million.
$460M
aggregate principal amount of 0.00% Convertible Senior Notes due 2032
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 4 signals
Tempus entered agreements with AstraZeneca and Pathos to develop, validate, and maintain a foundation large multimodal model in oncology, licensing de-identified multimodal data and committing $35 million to Pathos.
$35M
payment to Pathos for Foundation Model commitments
AIgenerative AIFoundation Modellarge multimodal model
Showing 10 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Tempus AI earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Entering $193M five-year data licensing deals with BMS and PathosTempus entered multi-year strategic collaborations to license oncology data and models to Bristol Myers Squibb for up to $138 million, while partnering with BMS and Pathos to build Alzheimer's data sets for $55 million. Over the five-year term, these agreements are expected to generate $193 million in data and applications revenue. This expansion signals significant pharma data pipeline... | |
| Revenue grew 23% to $412M with $25.6M adjusted EBITDAThird-quarter revenue reached $412 million, representing 23% year-over-year growth, driven by a 32% unit volume increase in Oncology and 33% revenue growth in Data and Applications. The company achieved positive adjusted EBITDA of $25.6 million, reaching a cash and marketable securities balance of $854 million. | |
| Pivoting clinical trial matching business to enterprise biopharma modelTempus restructured its TIME real-time clinical trial matching business from a biotech marketplace model to an enterprise-focused offering targeted at its largest biopharma partners. The network connects over a thousand oncologists across the U.S. and currently operates with a client waitlist. Meanwhile, management is intentionally deemphasizing traditional contract research organization (CRO)... | |
| Diagnostics revenue rose 20% to $304M, Oncology up 28%Diagnostics revenue reached $304 million (+20% YoY), driven by Oncology revenues of $173 million (+28% YoY) on 32% volume growth. Hereditary cancer testing contributed $111 million, with volume growth recovering to low double digits in September and October. | |
| Competing with Natera in MRD and Foundation Medicine in solid tumorTempus highlighted its competitive positioning across oncology diagnostic segments, asserting it ranks number 1 or number 2 in solid tumor, liquid biopsy, and hereditary profiling. Management compared its current market push in minimal residual disease (MRD) against Natera to its historical battle against Foundation Medicine in solid tumor profiling. Guardant Health was also cited as a primary... | |
| Absorbing cash burn and gross margin losses from Personalis acquisitionPersonalis currently generates negative gross profit on individual MRD test runs, which Tempus will need to absorb following the transaction's close. Management plans to allocate roughly two-thirds of incremental gross profit dollars to reinvestment, specifically to absorb Personalis' operating burn until reimbursement approvals allow the tests to achieve positive unit economics. Full... |
Signal API · MCP
Track Tempus AI with the Signal API
One POST /v1/companies/enrich call with tempus.com returns Tempus AI 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"tempus.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Tempus AI 10-Q
When did Tempus AI file its latest 10-Q?
What did Tempus AI disclose in its latest 10-Q?
What did Tempus AI say on its recent earnings calls?
Where can I read Tempus AI's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .